Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome

Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome - Posttransplant Vorinostat therapy against mycosis fungoides/Sezary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010774

Enrollment

Registered

2013-06-01

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mycosis fungoides/Sezary syndrome

Interventions

100mg of Vorinostat is added from day 28 posttransplantation. If the adverse effect etc is permissive in initial 2 weeks, the dose of Vorinostat is increased up to 200mg thereafter. Vorinostat is cont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients must have more than Stage IIB of mycosis fungoides/Sezary syndrome (1)Patients who have an appropriate related or unrelated donor described in the protocol. (2)From 16 to 65 years old (3)ECOG performance status of 0, 1 or 2 (4)Good major organ functions (lung, kidney, liver, heart) (5)Suitable to receive a reduced intensity transplant regimen in this trial (6)Patients who agree with this trial by informed consent form (in cases under age, getting agreement also by (legal) representative)

Exclusion criteria

Exclusion criteria: (1)Diabetes uncontrollable (2)Uncontrollable hypertension. (3)Current active infection. (4)Hepatitis B virus antigen (HBsAg), Hepatitis C virus RNA, or HIV antibody- positive. (5)Current active cancer. (6)Pregnant or nursing women or women who may be pregnant. (7)Uncontrollable mental illness. (8)Other unsuitable reasons

Design outcomes

Primary

Measure	Time frame
More than grade 4 (NCI-CTCAE version 4.0) of non-hematological toxicity within day 180 after allogeneic stem cell transplantation	—

Countries

Japan

Contacts

Public ContactSouichi Shiratori

Hokkaido university hospital Department of Hematology

s.shiratori@med.hokudai.ac.jp011-706-7214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026